Antidepressants and suicidality: the basis of controversies.
Regulatory agencies of different European countries and the United States have been critically examining the possible link between suicidality and antidepressant use in children and adults, which has resulted in an FDA directive to the manufacturers of all antidepressant medications to add a 'black box' warning. 'Black box' warning describes the increased risk of suicidality in persons who take antidepressants. Because the news media's coverage of the antidepressant-suicide controversy has increased dramatically in the last few years, serious concerns need to be performed. In this review, the possible risk-benefit ratio has been estimated according to the use of selective serotonin reuptake inhibitors (SSRIs) antidepressants due to relevant psychobiological, clinical and epidemiologic data.
Marcinko
Darko
D
Department of Psychiatry, University Hospital Zagreb, Kispatićeva 12, 10000 Zagreb, Croatia. darko.marcinko@zg.t-com.hr
D000328:Adult; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects; D000929:Antidepressive Agents, Tricyclic / Q000008:administration & dosage / Q000009:adverse effects; D002648:Child; D003866:Depressive Disorder / Q000188:drug therapy* / Q000401:mortality; D004348:Drug Labeling; D006801:Humans; D016017:Odds Ratio; D018570:Risk Assessment; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects; D013405:Suicide / Q000706:statistics & numerical data*; D014481:United States; D014486:United States Food and Drug Administration; D000092864:Suicide Prevention
D000928:Antidepressive Agents; D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D017367:Selective Serotonin Reuptake Inhibitors